Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
14:53:01 EDT Mon 29 Apr 2024
Enter Symbol
or Name
USA
CA



News for U:DYN from 2023-04-30 to 2024-04-29 - 25 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-03-27 16:05U:DYNNews ReleaseDyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
2024-03-27 08:30U:DYNNews ReleaseDyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
2024-03-25 07:30U:DYNNews ReleaseDyne Therapeutics Announces CEO Transition
2024-03-13 07:30U:DYNNews ReleaseDyne Therapeutics to Present at Stifel 2024 Virtual CNS Days
2024-03-05 07:30U:DYNNews ReleaseDyne Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
2024-02-14 16:15U:DYNNews ReleaseDyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
2024-02-01 07:30U:DYNNews ReleaseDyne Therapeutics to Present at February Investor Conferences
2024-01-11 16:05U:DYNNews ReleaseDyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
2024-01-05 07:30U:DYNNews ReleaseDyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
2024-01-04 22:47U:DYNNews ReleaseDyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock
2024-01-03 16:25U:DYNNews ReleaseDyne Therapeutics Announces Proposed Public Offering of Common Stock
2024-01-03 06:30U:DYNNews ReleaseDyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE ¢ „ ¢ Platform in Developing Therapeutics for Rare Muscle Diseases
2024-01-02 16:05U:DYNNews ReleaseDyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials
2023-11-07 07:30U:DYNNews ReleaseDyne Therapeutics to Present at November Investor Conferences
2023-10-30 07:30U:DYNNews ReleaseDyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones
2023-09-28 07:30U:DYNNews ReleaseDyne Therapeutics to Present at October Investor Conferences
2023-09-20 16:05U:DYNNews ReleaseDyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
2023-09-05 07:30U:DYNNews ReleaseDyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-03 07:30U:DYNNews ReleaseDyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
2023-06-01 07:30U:DYNNews ReleaseDyne Therapeutics to Present at Jefferies Healthcare Conference
2023-05-25 07:30U:DYNNews ReleaseDyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101
2023-05-17 07:30U:DYNNews ReleaseDyne Therapeutics ¢ € ™ Preclinical Data Demonstrating FORCE ¢ „ ¢ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting
2023-05-11 07:30U:DYNNews ReleaseDyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
2023-05-03 07:35U:DYNNews ReleaseDyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference
2023-05-02 16:46U:DYNNews ReleaseDyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE ¢ „ ¢ Platform Delivery to CNS